Notification of Commencement of Phase I Clinical Trials. Within thirty (30) days of Commencement of the first Phase I Clinical Trial for each Product, Licensee shall provide Licensor written notice of such Commencement and such notice shall (i) specifically identify the Commercial Target for such Product and (ii) specifically identify the Product being developed.
Appears in 3 contracts
Samples: Non Exclusive License Agreement (Allakos Inc.), Non Exclusive License Agreement (Allakos Inc.), Non Exclusive License Agreement (Allakos Inc.)
Notification of Commencement of Phase I Clinical Trials. Within thirty (30) [***] days of Commencement of the first Phase I Clinical Trial Trials for each Product, Licensee shall provide Licensor written notice of such Commencement of such Trial and such notice shall (i) specifically identify the Commercial Target for such Product Target; and (ii) specifically identify the Antibody or Product being developed.. [***] CONFIDENTIAL PORTIONS OF THIS DOCUMENT REDACTED AND FILED SEPARATELY WITH THE COMMISSION
Appears in 1 contract
Samples: Non Exclusive License Agreement (Kalobios Pharmaceuticals Inc)
Notification of Commencement of Phase I Clinical Trials. Within thirty *** (30***) days of Commencement of the first Phase I Clinical Trial for each Product, Licensee shall provide Licensor written notice of such Commencement and such notice shall (i) specifically identify the Commercial Target for such Product and (ii) specifically identify the Product being developed.
Appears in 1 contract
Samples: Non Exclusive License Agreement (Five Prime Therapeutics Inc)
Notification of Commencement of Phase I Clinical Trials. Within thirty (30) fifteen [***] days of Commencement of the first Phase I Clinical Trial Trials for each Product, Licensee shall provide Licensor written notice of such Commencement of such Trial and such notice shall (i) specifically identify the Commercial Target for such Product Target; and (ii) specifically identify the Antibody or Product being developed.
Appears in 1 contract
Samples: Non Exclusive License Agreement (Kalobios Pharmaceuticals Inc)
Notification of Commencement of Phase I Clinical Trials. Within thirty (30) days of Commencement of the first Phase I Clinical Trial for each Product, Licensee shall provide Licensor written notice of such Commencement and such notice shall (i) specifically identify the Commercial Target for such Product and (ii) specifically identify the Product being developed. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.
Appears in 1 contract
